Services
MRO
Resources
Company
Blog
Login
Search

>
Site Map

Site Map

NAMSA
About Us
Account
Activity
Careers at NAMSA
- Open Positions
- Total Rewards
Client Testimonials
Clinical Training
Code Analysis and Applications
Contact Us
Contract Research Organization Services
- Clinical Research Services
- Medical Device Consulting
- Medical Device Testing Services
- Our Therapeutic Expertise
- Testing
Cornerstone Draft
courses-dashboard
Do you know who is doing your biocompatibility testing?
EU MDR & IVDR Planning Resources
European Union’s General Data Protection Regulation Frequently Asked Questions – Clients
European Union’s General Data Protection Regulation Frequently Asked Questions – Vendors
event registration
event replay
Events
Health Economics Analysis
IVD & Companion Diagnostics Expertise
IVD CRO OVERVIEW
IVD EXPERTISE
IVD SERVICES
live-event
login
Make an Appointment
Materials Characterization Matrix
Medical Device Reimbursement Consulting
Medical Policy Research and Coverage Advocacy
Members
Membership List
MRO and CRO Comparison
NAMSA BIOCOMPATIBILITY STRATEGY NAVIGATOR
- Email Your Recommendations
- Email Your Recommendations
- Request a Quote Based on Your Recommendations
- Request a Quote Based on Your Recommendations
NAMSA Blog: News, Trends & Education
NAMSA Cookies Policy
NAMSA EU – U.S. and Swiss – U.S. Privacy Shield
NAMSA France
NAMSA Germany
NAMSA Latin America
NAMSA Launches New Analytical Services Laboratory in Germany
- Thank You for Registering for NAMSA’s Grand Opening in GERMANY!
NAMSA MRO Summits
NAMSA Purchasing Terms and Conditions
NAMSA Test Navigator
NAMSA’s Client Standard Terms and Conditions
oneclick-registration
Our Accreditations & Certifications
Our Global CRO Locations
- Americas
- Asia
- Europe
- Middle East
Our History: From CRO to MRO
Our Values: Integrity, Sustainability, Efficiency
Privacy Policy
Product Adoption Support
Product Development Strategy
Protected Content
Protected Content
Registration
Registration Cancelled
Registration Checkout
Resources
- Education
  - Medical Device Development E-Learning
  - Medical Device Topics Training Series
- Events
  - Categories
  - Locations
  - My Bookings
  - Tags
- Glossary of Terms
- Medical Device Development & Regulatory Webinars
- Podcasts
- Resource Library: Information for Medical Device Developers
- Useful Links for Medical Device Manufacturers
Sample Submission Forms
Site Map
Sterilization Products
Store
- Cart
- Checkout
- Order Status
- Products
Subscribe to the NAMSA Network
Terms of Use
test
Test Slider
Test webinar
thank you
Thank You
Thank You for Contacting NAMSA!
Thank You for Registering
Thank-You Page
Transactions
Understanding Europe’s MDR and IVDR
Webinar Countdown (Mandatory page, please do not modify or delete [EasyWebinarPlugin])
Webinar Error (Mandatory page, please do not modify or delete [EasyWebinarPlugin])
What Is A Medical Research Organization?
- Medical Research Organization
- Our Strategic Partners
- Stage 1 Medical Device Development Services: Concepting & Feasibility
- Stage 2 Medical Device Development Services: Design Validation/Preclinical Testing
- Stage 3 Medical Device Development Services: Clinical
- Stage 4 Medical Device Development Services: Market Approval
- Stage 5 Medical Device Development Services: Post-Market
Asian Market
- Chinese State Drug Administration Releases ‘Notice on the Implementation of Electronic Declaration of Medical Device Registration’
- NAMSA® Launches Chinese Website to Provide Medical Device Development Resource to APAC Sponsors
- Japan’s PMDA to Raise Medical Device and IVD Registration User Fees Beginning April 2018
- CFDA Releases Technical Guidelines for the Acceptance of Overseas Clinical Trial Data of Medical Devices
- CFDA Releases “Amendments to the Regulations on the Supervision and Administration of Medical Devices” Exposure Draft
- Japan’s “Ninsho Kijun” Regulatory Approval Pathway
- New Medical Device Classification Catalog Issued by the CFDA
- Japan’s PMDA Consultation Offering: A Beneficial Resource for Streamlined Device Approval
- NAMSA Launches Japanese Website to Support Increased Demand for Medical Device Development Services
- Focus on Japan Series: Part IV - Streamlining the Quality Management System Approval Process
- China Releases Regulations for the Supervision and Administration of Medical Devices (No. 680)
- Focus on Japan Series: Part III - Registering Facilities under Foreign Manufacturer Accreditation (FMA)
- CFDA Announces “Administrative Measures on Communication with Applicants for the Technical Evaluation of Medical Device (Trial)"
- Ensuring the Confidentiality of Chinese Medical Device Manufacturers
- Focus on Japan Series: Part I - Important Factors for Medical Device Development in Japan
- Guidelines for Medical Device Development in Japan
- CFDA Issues Announcement on Medical Device Priority Approval Procedures
- CFDA Provisions for Medical Device Adverse Event Monitoring and Re-evaluation
- The Three Pathways to Medical Device Registration in Japan
- CFDA Oversea GMP Inspections
- New Marketing Application Procedure for Combination Products in Japan
- CFDA Releases Notice Regarding GSP Compliance for Medical Device Manufacturers
- Definition of “Regenerative Medical Products” in Japanese Law Has Been Revised
- CFDA is Collecting Comments on Clinical Exemption Catalogue
- The Strategy of SAKIGAKE and How It Applies to Medical Devices
- Regenerative Medicine-Related Organizations and Activities in Japan
- CFDA and NHFPC Jointly Issue Decree No. 25 The Good Clinical Practice for Medical Devices
- PMDA Submission Strategy and CRO Limitations, Part 2
- CFDA Authenticity Verification of Clinical Trial Data for Medical Device Kick Off
- Steady Growth for China's Medical Device Fast Track Process
- PMDA Submission Strategy and CRO Limitations, Part 1
- China Acceptance of Foreign Biocompatibility Reports
- Announcing Construction of New Preclinical Laboratory for Medical Device Research in Shanghai, China
- China Regulation Updates
- CFDA Regulation Creates Changes in Chinese Regulatory Landscape
- Chinese Medical Device Market Continues to Grow
- The 2014 BPMDS Kicks Off In Germany
- NAMSA China Expands Expertise and Services
- Emerging Markets Theater - Life Science Alley Conference
Chemical Characterization
- NAMSA Launches Online Biocompatibility Strategy Application to Streamline Development Efforts for Global Medical Device Manufacturers
- White Paper: Utilizing Biological Risk Assessments and Chemical Characterization to Reduce Medical Device Development Timelines
Clinical
- NAMSA® Launches Chinese Website to Provide Medical Device Development Resource to APAC Sponsors
- NAMSA® Launches Market Intelligence Report on Global Medical Device Clinical Outsourcing Trends
- NAMSA® Launches "Uniquely IVD" Development Services to Expedite in vitro Diagnostic Technology Commercialization Efforts for Global Manufacturers
- NAMSA Recognized as Leading Medical Device CRO for Second Consecutive Year by Life Science Leader
- NAMSA Introduces French Website to Provide Resource for Accelerated Medical Device Development in Europe
- NAMSA Launches Japanese Website to Support Increased Demand for Medical Device Development Services
- NAMSA Expands Medical Device Clinical and Consulting Services Presence in Minneapolis to Accommodate Growth
- Update on FDA’s Clinical Trials Program for Medical Devices
- NAMSA White Paper: Risk-Based Monitoring: Exploring the Clinical Site Experience
- PMDA Submission Strategy and CRO Limitations, Part 2
- CFDA Authenticity Verification of Clinical Trial Data for Medical Device Kick Off
- Medical Device Clinical Trials: SAE reporting requirements in Germany and Austria
- Medical Device Development: Clinical Studies, Part 2
- NAMSA Expands Service Offering Expertise Into South America
- NAMSA White Paper: Risk-Based Monitoring: Considerations for Clinical Implementation
- Medical Device Development: Clinical Studies, Part 1
- NAMSA White Paper: FDA Pre-Submission or Q-Sub Program
- NAMSA White Paper: Risk-Based Monitoring: Setting up the Structure for a Systematic Approach
- NAMSA and Fortuna Clinical Form Strategic Relationship
- NAMSA White Paper: Human Factors Studies in Medical Device Reprocessing
- NAMSA White Paper: Risk-Based Monitoring: A Cognizant Approach
- Infographic: Common Mistakes in the Medical Device Development Continuum
- NAMSA White Paper: Joining Preclinical and Clinical Development: A Practical Approach to Reducing Medical Device Timelines
- FDA Draft Guidance on Acceptance of Medical Device Clinical Data from Studies Conducted Outside the US
- Additional Information You Should Know Before Performing a Clinical Study
- Obstacles in European Clinical Trials
- Differences and Similarities in Investigator Selection Between the US and EU
- Things to Consider When Selecting a Clinical Investigator
- Selecting a CRO for Clinical Research
- Selecting an Optimal Study Site in the EU
- China Regulation Updates
- Conducting a Clinical Study in the US
- Remote Monitoring in Clinical Testing
- Responsibilities of an Authorized Representative and US Agent
- Updating a Clinical Evaluation Report (CER)
- The Need for an Agent for Clinical Trials in the US
- The Need for an Authorized Representative for Clinical Trials in the EU
- Insights for Clinical Management
- Meet with NAMSA on the Road
- FDA Gives New IVD Guidance
- Emerging Markets Theater - Life Science Alley Conference
- Developing a European First-In-Human (FIH) Study
- Remote Training Seminars Now Offered By NAMSA
Consulting
- Chinese State Drug Administration Releases ‘Notice on the Implementation of Electronic Declaration of Medical Device Registration’
- EU IVDR: Understanding the New QMS Requirements
- Three Essentials for Smart IVD Clinical Trial Design
- FDA CDRH: New Organizational Structure Effective May 1, 2019
- Draft Corrigenda for EU MDR and IVDR Released
- EMA Issues Q&A Regarding Impact of MDR, Article 117
- EU Issues Q&A Document to Provide Further Analysis of Potential No-Deal Brexit
- UK MHRA Releases Contingency Legislation Covering Regulation of Medical Devices in Brexit ‘No Deal’ Scenario
- EU Commission Updates Website to Provide Additional MDR and IVDR Planning Resources
- Renewal Timelines Quickly Approaching for Medical Device Directive (MDD:M5) CE Mark Certificates
- FDA Shifts 510(K) Paradigm, Announces Transformative Steps to Modernize 510(k) Program
- EU Commission & MDCG Release New MDR & IVDR Guidance Documents
- FDA CDRH Reorganization: Faster Reviews for Medical Device Manufacturers?
- Effective Implementation of EN ISO 14971 Medical Device Risk Management Standard
- FDA Announces FY19 User Fees
- EU Commission Issues Supplementary Guidance Information for CE Marks Under MDR & IVDR
- NAMSA® Launches "Uniquely IVD" Development Services to Expedite in vitro Diagnostic Technology Commercialization Efforts for Global Manufacturers
- Mid-Year FDA Regulation & Guidance Review
- FDA Issues New Draft Guidance Document for Pre-Submissions
- EU MDR and IVDR Compliance Planning Resources
- NAMSA Recognized as Leading Medical Device CRO for Second Consecutive Year by Life Science Leader
- CE Marking of Digital Health Technologies: Stricter Rules for Medical Device Software under the EU MDR
- Japan’s PMDA to Raise Medical Device and IVD Registration User Fees Beginning April 2018
- NAMSA Introduces French Website to Provide Resource for Accelerated Medical Device Development in Europe
- EU Commission Issues “Notice to Stakeholders: Withdrawal of the United Kingdom and EU Rules in the Field of Industrial Products”
- Obtaining Actionable FDA Feedback: How to Develop Targeted Questions for Pre-Submission Meetings
- ISO 13485:2016 - Effective Preparation and Implementation of Medical Device Quality Management Systems
- Japan’s “Ninsho Kijun” Regulatory Approval Pathway
- Japan’s PMDA Consultation Offering: A Beneficial Resource for Streamlined Device Approval
- NAMSA Launches Japanese Website to Support Increased Demand for Medical Device Development Services
- Focus on Japan Series: Part IV - Streamlining the Quality Management System Approval Process
- Focus on Japan Series: Part III - Registering Facilities under Foreign Manufacturer Accreditation (FMA)
- Focus on Japan Series: Part II - Understanding the Designated Marketing Authorization (D-MAH) Status for Foreign Device Manufacturers
- NAMSA Expands Medical Device Clinical and Consulting Services Presence in Minneapolis to Accommodate Growth
- FDA Warning Letters for Non-US Manufacturers
- FDA Factors to Consider Regarding Benefit - Risk in Medical Device Product Availability, Compliance, and Enforcement Decisions
- New Marketing Application Procedure for Combination Products in Japan
- CFDA Releases Notice Regarding GSP Compliance for Medical Device Manufacturers
- The New European MDR – Harmonization Effort with International Regulatory Requirements for Medical Devices
- FDA Finalizes Biocompatibility Guidance for Medical Devices
- FDA Issues ‘Leap-Frog’ Guidance for 3D-Printed Medical Devices
- CFDA is Collecting Comments on Clinical Exemption Catalogue
- Human Factors / Usability Engineering in Product Design and Development
- Is 2016 The Year That CMS Starts Fining Sunshine Act Violators?
- Unannounced Notified Body Audit
- FDA Clarifies Policy for Color Additives in Medical Devices
- Regenerative Medicine-Related Organizations and Activities in Japan
- CFDA and NHFPC Jointly Issue Decree No. 25 The Good Clinical Practice for Medical Devices
- PMDA Submission Strategy and CRO Limitations, Part 2
- CFDA Authenticity Verification of Clinical Trial Data for Medical Device Kick Off
- ISO 13485:2016 - Medical devices – Quality management systems – Requirements for regulatory purposes
- The Importance of Applying Human Factors and Usability Engineering to Medical Devices
- Steady Growth for China's Medical Device Fast Track Process
- PMDA Submission Strategy and CRO Limitations, Part 1
- Regulatory
  - Chinese State Drug Administration Releases ‘Notice on the Implementation of Electronic Declaration of Medical Device Registration’
  - EU IVDR: Understanding the New QMS Requirements
  - FDA CDRH: New Organizational Structure Effective May 1, 2019
  - Draft Corrigenda for EU MDR and IVDR Released
  - EMA Issues Q&A Regarding Impact of MDR, Article 117
  - EU Issues Q&A Document to Provide Further Analysis of Potential No-Deal Brexit
  - UK MHRA Releases Contingency Legislation Covering Regulation of Medical Devices in Brexit ‘No Deal’ Scenario
  - EU Commission Updates Website to Provide Additional MDR and IVDR Planning Resources
  - Renewal Timelines Quickly Approaching for Medical Device Directive (MDD:M5) CE Mark Certificates
  - FDA Shifts 510(K) Paradigm, Announces Transformative Steps to Modernize 510(k) Program
  - NAMSA® Launches Chinese Website to Provide Medical Device Development Resource to APAC Sponsors
  - NAMSA® Launches Market Intelligence Report on Global Medical Device Clinical Outsourcing Trends
  - EU Commission & MDCG Release New MDR & IVDR Guidance Documents
  - FDA CDRH Reorganization: Faster Reviews for Medical Device Manufacturers?
  - Effective Implementation of EN ISO 14971 Medical Device Risk Management Standard
  - FDA Announces FY19 User Fees
  - EU Commission Issues Supplementary Guidance Information for CE Marks Under MDR & IVDR
  - NAMSA® Launches "Uniquely IVD" Development Services to Expedite in vitro Diagnostic Technology Commercialization Efforts for Global Manufacturers
  - Mid-Year FDA Regulation & Guidance Review
  - FDA Issues New Draft Guidance Document for Pre-Submissions
  - EU MDR and IVDR Compliance Planning Resources
  - NAMSA Recognized as Leading Medical Device CRO for Second Consecutive Year by Life Science Leader
  - CE Marking of Digital Health Technologies: Stricter Rules for Medical Device Software under the EU MDR
  - Japan’s PMDA to Raise Medical Device and IVD Registration User Fees Beginning April 2018
  - NAMSA Introduces French Website to Provide Resource for Accelerated Medical Device Development in Europe
  - CFDA Releases Technical Guidelines for the Acceptance of Overseas Clinical Trial Data of Medical Devices
  - EU Commission Issues “Notice to Stakeholders: Withdrawal of the United Kingdom and EU Rules in the Field of Industrial Products”
  - Obtaining Actionable FDA Feedback: How to Develop Targeted Questions for Pre-Submission Meetings
  - ISO 13485:2016 - Effective Preparation and Implementation of Medical Device Quality Management Systems
  - CFDA Releases “Amendments to the Regulations on the Supervision and Administration of Medical Devices” Exposure Draft
  - Japan’s “Ninsho Kijun” Regulatory Approval Pathway
  - Brexit and the Impact on UK Medical Device Operations
  - The Importance of Human Factors & Usability Engineering in Medical Devices
  - UK MHRA Publishes Guide to the New EU Medical Device and IVD Regulations
  - New Medical Device Classification Catalog Issued by the CFDA
  - The Value of Randomized Pilot Studies in Demonstrating Patient Safety and Efficacy
  - Japan’s PMDA Consultation Offering: A Beneficial Resource for Streamlined Device Approval
  - EU MDR Poses Significant Changes for Importers and Distributors
  - NAMSA Launches Japanese Website to Support Increased Demand for Medical Device Development Services
  - Focus on Japan Series: Part IV - Streamlining the Quality Management System Approval Process
  - China Releases Regulations for the Supervision and Administration of Medical Devices (No. 680)
  - Risk: An Emerging Driver for New Regulatory Requirements
  - Focus on Japan Series: Part III - Registering Facilities under Foreign Manufacturer Accreditation (FMA)
  - CFDA Announces “Administrative Measures on Communication with Applicants for the Technical Evaluation of Medical Device (Trial)"
  - MDR Transition Timelines for Legacy Medical Devices - Not without Risks and Undue Burden
  - Good News for Industry? How the Proposed FDA Class II Device Exemptions Will Impact Medical Device Manufacturers
  - EU Parliament Votes to Institute the New IVDR and MDR Regulations; Transition Period Expected to Begin on June 1, 2017
  - Why Regional Reimbursement Strategies Could Be Right For Medtech
  - France Imposes New Registration Requirement for Implantable and Class III Medical Device Manufacturers
  - Focus on Japan Series: Part II - Understanding the Designated Marketing Authorization (D-MAH) Status for Foreign Device Manufacturers
  - Planning for Success: UDI Requirements Under the EU MDD/MDR
  - Ensuring the Confidentiality of Chinese Medical Device Manufacturers
  - 2017 Medical Device Outlook: Five Potential Impacts to Global Device Organizations
  - Focus on Japan Series: Part I - Important Factors for Medical Device Development in Japan
  - Important Considerations for Labelling of Medical Devices Under the New EU MDR
  - Guidelines for Medical Device Development in Japan
  - Clinical Trials for Innovative Devices: Concurrent Review by FDA/CMS Leads to Time and Cost Efficiencies
  - CFDA Issues Announcement on Medical Device Priority Approval Procedures
  - CFDA Provisions for Medical Device Adverse Event Monitoring and Re-evaluation
  - The Three Pathways to Medical Device Registration in Japan
  - ISO 13485:2016 and Risk Management
  - Do I Need to Submit a New 510(k)?
  - CFDA Oversea GMP Inspections
  - FDA Warning Letters for Non-US Manufacturers
  - FDA Factors to Consider Regarding Benefit - Risk in Medical Device Product Availability, Compliance, and Enforcement Decisions
  - MEDDEV 2.7.1 Revision 4 – Stricter Requirements for Clinical Evaluation Reports
  - Update on FDA’s Clinical Trials Program for Medical Devices
  - New Marketing Application Procedure for Combination Products in Japan
  - CFDA Releases Notice Regarding GSP Compliance for Medical Device Manufacturers
  - The New European MDR – Harmonization Effort with International Regulatory Requirements for Medical Devices
  - FDA Finalizes Biocompatibility Guidance for Medical Devices
  - Definition of “Regenerative Medical Products” in Japanese Law Has Been Revised
  - FDA Issues ‘Leap-Frog’ Guidance for 3D-Printed Medical Devices
  - CFDA is Collecting Comments on Clinical Exemption Catalogue
  - Human Factors / Usability Engineering in Product Design and Development
  - The Strategy of SAKIGAKE and How It Applies to Medical Devices
  - New Pre-Market Scrutiny Process for High-Risk Products in Europe
  - Industry Survey: FDA's Focus on Early Feasibility Studies
  - Unannounced Notified Body Audit
  - FDA Clarifies Policy for Color Additives in Medical Devices
  - Regenerative Medicine-Related Organizations and Activities in Japan
  - CFDA and NHFPC Jointly Issue Decree No. 25 The Good Clinical Practice for Medical Devices
  - PMDA Submission Strategy and CRO Limitations, Part 2
  - CFDA Authenticity Verification of Clinical Trial Data for Medical Device Kick Off
  - ISO 13485:2016 - Medical devices – Quality management systems – Requirements for regulatory purposes
  - The Importance of Applying Human Factors and Usability Engineering to Medical Devices
  - Steady Growth for China's Medical Device Fast Track Process
  - PMDA Submission Strategy and CRO Limitations, Part 1
  - Upcoming UDI Requirements and 2016 Compliance Dates for Labelers of Class II Medical Devices
  - China Acceptance of Foreign Biocompatibility Reports
  - Medical Device Development: Post-Market
  - Medical Device Development: Market Approval
  - Medical Device Development: Clinical Studies, Part 2
  - NAMSA White Paper: Risk-Based Monitoring: Considerations for Clinical Implementation
  - Medical Device Development: Clinical Studies, Part 1
  - Medical Device Development: Design Validation and Preclinical, Part 2
  - Medical Device Development: Design Validation and Preclinical, Part 1
  - NAMSA and Fortuna Clinical Form Strategic Relationship
  - Medical Device Development: Concept and Feasibility, Part 2
  - Medical Device Development: Concept and Feasibility, Part 1
  - Infographic: Common Mistakes in the Medical Device Development Continuum
  - NAMSA White Paper: Joining Preclinical and Clinical Development: A Practical Approach to Reducing Medical Device Timelines
  - Impacts and Obstacles of Innovation in Medical Devices
  - FDA Draft Guidance on Acceptance of Medical Device Clinical Data from Studies Conducted Outside the US
  - Emerging and Re-Emerging Markets : How to Navigate Innovation Through Global Regulatory Approvals
  - Additional Information You Should Know Before Performing a Clinical Study
  - Examining the Progress of the Ongoing Revision of the Medical Device Directive
  - Moving From In Vitro to In Vivo: What Happens Next?
  - Differences and Similarities in Investigator Selection Between the US and EU
  - Things to Consider When Selecting a Clinical Investigator
  - De Novo Classification Process
  - FDA Guidance on Exemptions for Custom Devices
  - Selecting a CRO for Clinical Research
  - Selecting an Optimal Study Site in the EU
  - Updated German Legislation for Medical Devices
  - New Developments in FDA Biocompatibility Requirements for Personal Lubricants
  - China Regulation Updates
  - Conducting a Clinical Study in the US
  - New FDA Regulations on Laboratory-Developed Tests
  - Responsibilities of an Authorized Representative and US Agent
  - Updating a Clinical Evaluation Report (CER)
  - Bringing a Novel Medical Device or IVD to Market
  - The Need for an Agent for Clinical Trials in the US
  - EU Borderline Classification Manual Update
  - The Need for an Authorized Representative for Clinical Trials in the EU
  - Revised Code of Conduct for Notified Bodies
  - Update on the New EU IVD and Medical Device Regulations
  - Informed Consent - Time for Change
  - Insights for Clinical Management
  - Engaging the Best Notified Body to Certify Your Device in the EU
  - Meet with NAMSA on the Road
  - The FDA Acceptance Review and Refuse To Accept Processes for PMAs and 510(k)s
  - Unique Device Identifier Required for Class III Medical Devices
  - NAMSA Speakers Around the Globe
  - Optimizing Your Journey on the IDE Approval Pathway: The FDA Pre-Submission Program
  - CFDA Regulation Creates Changes in Chinese Regulatory Landscape
  - New FDA Guidance Regarding CLIA Categorization Process for IVDs
  - Final Pre-Submission Guidance Issued by FDA
  - Chinese Medical Device Market Continues to Grow
  - FDA Gives New IVD Guidance
  - NAMSA China Expands Expertise and Services
  - New Acceptance Review Processes for 510(k)s and PMAs
  - Remote Training Seminars Now Offered By NAMSA
European Market
- Draft Corrigenda for EU MDR and IVDR Released
- EMA Issues Q&A Regarding Impact of MDR, Article 117
- EU Issues Q&A Document to Provide Further Analysis of Potential No-Deal Brexit
- UK MHRA Releases Contingency Legislation Covering Regulation of Medical Devices in Brexit ‘No Deal’ Scenario
- EU Commission Updates Website to Provide Additional MDR and IVDR Planning Resources
- Renewal Timelines Quickly Approaching for Medical Device Directive (MDD:M5) CE Mark Certificates
- EU Commission & MDCG Release New MDR & IVDR Guidance Documents
- Effective Implementation of EN ISO 14971 Medical Device Risk Management Standard
- EU Commission Issues Supplementary Guidance Information for CE Marks Under MDR & IVDR
- EU MDR and IVDR Compliance Planning Resources
- CE Marking of Digital Health Technologies: Stricter Rules for Medical Device Software under the EU MDR
- NAMSA Introduces French Website to Provide Resource for Accelerated Medical Device Development in Europe
- EU Commission Issues “Notice to Stakeholders: Withdrawal of the United Kingdom and EU Rules in the Field of Industrial Products”
- NAMSA Expands Medical Device Testing Services in Germany to Increase Access to Accelerated Product Development
- NAMSA Launches German Website to Support Europe’s Largest Medical Device Marketplace
- Brexit and the Impact on UK Medical Device Operations
- The Importance of Human Factors & Usability Engineering in Medical Devices
- UK MHRA Publishes Guide to the New EU Medical Device and IVD Regulations
- EU MDR Poses Significant Changes for Importers and Distributors
- Risk: An Emerging Driver for New Regulatory Requirements
- MDR Transition Timelines for Legacy Medical Devices - Not without Risks and Undue Burden
- EU Parliament Votes to Institute the New IVDR and MDR Regulations; Transition Period Expected to Begin on June 1, 2017
- France Imposes New Registration Requirement for Implantable and Class III Medical Device Manufacturers
- Planning for Success: UDI Requirements Under the EU MDD/MDR
- 2017 Medical Device Outlook: Five Potential Impacts to Global Device Organizations
- Important Considerations for Labelling of Medical Devices Under the New EU MDR
- ISO 13485:2016 and Risk Management
- FDA Warning Letters for Non-US Manufacturers
- MEDDEV 2.7.1 Revision 4 – Stricter Requirements for Clinical Evaluation Reports
- The New European MDR – Harmonization Effort with International Regulatory Requirements for Medical Devices
- Human Factors / Usability Engineering in Product Design and Development
- New Pre-Market Scrutiny Process for High-Risk Products in Europe
- Unannounced Notified Body Audit
- Medical Device Clinical Trials: SAE reporting requirements in Germany and Austria
- Obstacles in European Clinical Trials
- Differences and Similarities in Investigator Selection Between the US and EU
- Selecting a CRO for Clinical Research
- Selecting an Optimal Study Site in the EU
- Updated German Legislation for Medical Devices
- Responsibilities of an Authorized Representative and US Agent
- The Need for an Agent for Clinical Trials in the US
- EU Borderline Classification Manual Update
- The Need for an Authorized Representative for Clinical Trials in the EU
- Revised Code of Conduct for Notified Bodies
- Update on the New EU IVD and Medical Device Regulations
- Engaging the Best Notified Body to Certify Your Device in the EU
- CFDA Regulation Creates Changes in Chinese Regulatory Landscape
- Chinese Medical Device Market Continues to Grow
- The 2014 BPMDS Kicks Off In Germany
- Emerging Markets Theater - Life Science Alley Conference
- New EU Medical Device Legislation Proposal
- Developing a European First-In-Human (FIH) Study
FDA
- FDA CDRH: New Organizational Structure Effective May 1, 2019
- FDA Shifts 510(K) Paradigm, Announces Transformative Steps to Modernize 510(k) Program
- FDA CDRH Reorganization: Faster Reviews for Medical Device Manufacturers?
- FDA Announces FY19 User Fees
- Mid-Year FDA Regulation & Guidance Review
- FDA Issues New Draft Guidance Document for Pre-Submissions
- Obtaining Actionable FDA Feedback: How to Develop Targeted Questions for Pre-Submission Meetings
- ISO 13485:2016 - Effective Preparation and Implementation of Medical Device Quality Management Systems
- White Paper: Utilizing Biological Risk Assessments and Chemical Characterization to Reduce Medical Device Development Timelines
- The Value of Randomized Pilot Studies in Demonstrating Patient Safety and Efficacy
- Good News for Industry? How the Proposed FDA Class II Device Exemptions Will Impact Medical Device Manufacturers
- Why Regional Reimbursement Strategies Could Be Right For Medtech
- France Imposes New Registration Requirement for Implantable and Class III Medical Device Manufacturers
- Planning for Success: UDI Requirements Under the EU MDD/MDR
- 2017 Medical Device Outlook: Five Potential Impacts to Global Device Organizations
- Clinical Trials for Innovative Devices: Concurrent Review by FDA/CMS Leads to Time and Cost Efficiencies
- Do I Need to Submit a New 510(k)?
- FDA Factors to Consider Regarding Benefit - Risk in Medical Device Product Availability, Compliance, and Enforcement Decisions
- Update on FDA’s Clinical Trials Program for Medical Devices
- FDA Finalizes Biocompatibility Guidance for Medical Devices
- FDA Issues ‘Leap-Frog’ Guidance for 3D-Printed Medical Devices
- Industry Survey: FDA's Focus on Early Feasibility Studies
- FDA Clarifies Policy for Color Additives in Medical Devices
- The Importance of Applying Human Factors and Usability Engineering to Medical Devices
- Upcoming UDI Requirements and 2016 Compliance Dates for Labelers of Class II Medical Devices
- Medical Device Development: Post-Market
- Medical Device Development: Market Approval
- Traceability in Device Design, Development, and Distribution
- NAMSA White Paper: FDA Pre-Submission or Q-Sub Program
- NAMSA White Paper: Human Factors Studies in Medical Device Reprocessing
- NAMSA White Paper: Risk-Based Monitoring: A Cognizant Approach
- Infographic: Common Mistakes in the Medical Device Development Continuum
- Recommendations for Designing Studies for the Validation of Reprocessing Instructions
- FDA Draft Guidance on Acceptance of Medical Device Clinical Data from Studies Conducted Outside the US
- Don Palme at MD&M Minneapolis
- Moving From In Vitro to In Vivo: What Happens Next?
- Differences and Similarities in Investigator Selection Between the US and EU
- Package Validation
- De Novo Classification Process
- FDA Guidance on Exemptions for Custom Devices
- Medibio Has Appointed NAMSA to Assist with Trial Design and Regulatory Discussion with the US FDA
- The Basics of Bone Implantation, Part 1: Why Bone Implantation?
- New Developments in FDA Biocompatibility Requirements for Personal Lubricants
- New FDA Regulations on Laboratory-Developed Tests
- The Need for an Agent for Clinical Trials in the US
- Informed Consent - Time for Change
- FDA Guidelines for Social Media Posts with Character Limitations
- The FDA Acceptance Review and Refuse To Accept Processes for PMAs and 510(k)s
- Independent Assessment of FDA Device Review Program Results in 11 Recommendations
- Unique Device Identifier Required for Class III Medical Devices
- Optimizing Your Journey on the IDE Approval Pathway: The FDA Pre-Submission Program
- Reusable Medical Device
- Final Pre-Submission Guidance Issued by FDA
- FDA to Propose Guidelines For Interoperable Medical Devices
- FDA Gives New IVD Guidance
- New Acceptance Review Processes for 510(k)s and PMAs
- FDA Regulation of Mobile Medical Applications
Industry Reposts
- MEDDEV 2.7.1 Revision 4 – Stricter Requirements for Clinical Evaluation Reports
- Is 2016 The Year That CMS Starts Fining Sunshine Act Violators?
- Infographic: Common Mistakes in the Medical Device Development Continuum
- Updated German Legislation for Medical Devices
- FDA Guidelines for Social Media Posts with Character Limitations
- Independent Assessment of FDA Device Review Program Results in 11 Recommendations
- New FDA Guidance Regarding CLIA Categorization Process for IVDs
- Final Pre-Submission Guidance Issued by FDA
- FDA to Propose Guidelines For Interoperable Medical Devices
IVD
- EU IVDR: Understanding the New QMS Requirements
Microbiology
- NAMSA Launches Online Biocompatibility Strategy Application to Streamline Development Efforts for Global Medical Device Manufacturers
- White Paper: Utilizing Biological Risk Assessments and Chemical Characterization to Reduce Medical Device Development Timelines
- NAMSA Announces New Online Test Selection Tool to Support Global Medical Device Manufacturers
- Infographic: Common Mistakes in the Medical Device Development Continuum
- Recommendations for Designing Studies for the Validation of Reprocessing Instructions
- Introducing NAMSA Connect
- Reusable Medical Device
- NAMSA Irvine Facility Expands
MRO
- NAMSA® Launches Chinese Website to Provide Medical Device Development Resource to APAC Sponsors
- NAMSA® Launches Market Intelligence Report on Global Medical Device Clinical Outsourcing Trends
- NAMSA Launches Online Biocompatibility Strategy Application to Streamline Development Efforts for Global Medical Device Manufacturers
- NAMSA® Launches "Uniquely IVD" Development Services to Expedite in vitro Diagnostic Technology Commercialization Efforts for Global Manufacturers
- NAMSA Recognized as Leading Medical Device CRO for Second Consecutive Year by Life Science Leader
- The Value of Randomized Pilot Studies in Demonstrating Patient Safety and Efficacy
- NAMSA Expands Service Offering Expertise Into South America
- NAMSA and Fortuna Clinical Form Strategic Relationship
- Medical Device Development: Concept and Feasibility, Part 2
- Medical Device Development: Concept and Feasibility, Part 1
- Infographic: Common Mistakes in the Medical Device Development Continuum
- NAMSA White Paper: Joining Preclinical and Clinical Development: A Practical Approach to Reducing Medical Device Timelines
- NAMSA White Paper: MedTech Outsourcing: Is the Past Any Indication of the Future?
- China Regulation Updates
- Informed Consent - Time for Change
- Engaging the Best Notified Body to Certify Your Device in the EU
- NAMSA Receives AAALAC Accreditation for Preclinical Facility in Minnesota
- The FDA Acceptance Review and Refuse To Accept Processes for PMAs and 510(k)s
- Independent Assessment of FDA Device Review Program Results in 11 Recommendations
- Introducing NAMSA Connect
- NAMSA’s Cell Culture Capabilities
- Unique Device Identifier Required for Class III Medical Devices
- NAMSA's Anatomic Program
- Reusable Medical Device
- NAMSA China Expands Expertise and Services
- NAMSA Irvine Facility Expands
News
- NAMSA® Launches Chinese Website to Provide Medical Device Development Resource to APAC Sponsors
- NAMSA® Launches Market Intelligence Report on Global Medical Device Clinical Outsourcing Trends
- NAMSA Launches Online Biocompatibility Strategy Application to Streamline Development Efforts for Global Medical Device Manufacturers
- NAMSA® Launches "Uniquely IVD" Development Services to Expedite in vitro Diagnostic Technology Commercialization Efforts for Global Manufacturers
- NAMSA Recognized as Leading Medical Device CRO for Second Consecutive Year by Life Science Leader
- NAMSA Expands Service Network Expertise into Costa Rica
- NAMSA Expands Service Network Expertise into Brazil and Mexico
- NAMSA Announces Divestiture of its Sterility Assurance Products Division
- NAMSA Expands Service Offering Expertise Into South America
- NAMSA and Fortuna Clinical Form Strategic Relationship
- Announcing Construction of New Preclinical Laboratory for Medical Device Research in Shanghai, China
- Medibio Has Appointed NAMSA to Assist with Trial Design and Regulatory Discussion with the US FDA
- NAMSA Symposium Coming to China
- NAMSA Receives AAALAC Accreditation for Preclinical Facility in Minnesota
- Introducing NAMSA Connect
- Agenda Announced for Germany Symposium
- NAMSA Announces 2014 Remote Training Series Calendar
- The 2014 BPMDS Kicks Off In Germany
- NAMSA Acquires Medvance LTD., Expanding European Presence and Clinical and Consulting Services
- NAMSA Adds BMP-2 Assay to a Comprehensive Breadth of Solutions for DBM Testing
- NAMSA China Expands Expertise and Services
- Emerging Markets Theater - Life Science Alley Conference
- NAMSA Partners with Medipert
- NAMSA Irvine Facility Expands
- Remote Training Seminars Now Offered By NAMSA
- NAMSA to Sponsor and Speak at Biocompatibility and Performance of Medical Device Symposium in Minneapolis
- NAMSA Sponsoring Conference on Best Practices for Biocompatibility and Performance for Medical Devices
- NAMSA Expands State-Of-The-Art Laboratory in Lyon, France
- NAMSA Acquires The Integra Group, Expanding Imaging and Clinical Services
- NAMSA Rebrands Business Unit in France
- NAMSA Expands ICP Offering
- NAMSA Opens Frankfurt Office to Provide Clinical Trial and Regulatory Support
- NAMSA Renames Acquisition
- NAMSA to Expand Laboratory Facilities
- NAMSA Continues to Expand Materials Testing Capabilities
- 2012 Fee Schedule Update
- Press Release
  - NAMSA Recognized as Leading Medical Device CRO for Third Consecutive Year by Life Science Leader
  - NAMSA Announces Acquisition of Reimbursement Strategies, LLC, Expands Medical Device Development Portfolio
  - NAMSA® Launches Chinese Website to Provide Medical Device Development Resource to APAC Sponsors
  - NAMSA® Launches Market Intelligence Report on Global Medical Device Clinical Outsourcing Trends
  - NAMSA Launches Online Biocompatibility Strategy Application to Streamline Development Efforts for Global Medical Device Manufacturers
  - NAMSA® Launches "Uniquely IVD" Development Services to Expedite in vitro Diagnostic Technology Commercialization Efforts for Global Manufacturers
  - NAMSA Recognized as Leading Medical Device CRO for Second Consecutive Year by Life Science Leader
  - NAMSA Introduces French Website to Provide Resource for Accelerated Medical Device Development in Europe
  - NAMSA Expands Medical Device Testing Services in Germany to Increase Access to Accelerated Product Development
  - NAMSA Launches German Website to Support Europe’s Largest Medical Device Marketplace
  - NAMSA Announces New Online Test Selection Tool to Support Global Medical Device Manufacturers
  - NAMSA Launches Japanese Website to Support Increased Demand for Medical Device Development Services
  - NAMSA Celebrates 50 Years of Scientific Innovation in the Medtech Industry
  - NAMSA Recognized as a Premier International CRO by Life Science Leader
  - NAMSA and NAGLREITER Partner to Provide Innovative Development Solution to Global Medical Device Manufacturers
  - NAMSA Broadens Global Reach of Medical Device Development Summits to Increase Access to Industry Experts
  - NAMSA Expands Medical Device Clinical and Consulting Services Presence in Minneapolis to Accommodate Growth
  - NAMSA Expands Service Offering in China with Opening of Shanghai Laboratory
  - NAMSA Expands Service Network Expertise into Costa Rica
  - NAMSA Expands Service Network Expertise into Brazil and Mexico
  - NAMSA Announces Divestiture of its Sterility Assurance Products Division
  - NAMSA Expands Service Offering Expertise Into South America
  - NAMSA and Fortuna Clinical Form Strategic Relationship
  - Announcing Construction of New Preclinical Laboratory for Medical Device Research in Shanghai, China
  - NAMSA Acquires Medvance LTD., Expanding European Presence and Clinical and Consulting Services
  - NAMSA Acquires The Integra Group, Expanding Imaging and Clinical Services
Packaging & Stability
- Ready for DuPont’s Transition Tyvek®? NAMSA Can Help!!
- Medical Device Development: Design Validation and Preclinical, Part 2
- Medical Device Development: Design Validation and Preclinical, Part 1
- Infographic: Common Mistakes in the Medical Device Development Continuum
- Recommendations for Designing Studies for the Validation of Reprocessing Instructions
- Package Validation
- NAMSA Shelf Life Validation
Preclinical
- China Acceptance of Foreign Biocompatibility Reports
- NAMSA Expands Service Offering Expertise Into South America
- Traceability in Device Design, Development, and Distribution
- Medical Device Development: Design Validation and Preclinical, Part 2
- Medical Device Development: Design Validation and Preclinical, Part 1
- NAMSA and Fortuna Clinical Form Strategic Relationship
- Infographic: Common Mistakes in the Medical Device Development Continuum
- NAMSA White Paper: Joining Preclinical and Clinical Development: A Practical Approach to Reducing Medical Device Timelines
- Announcing Construction of New Preclinical Laboratory for Medical Device Research in Shanghai, China
- Evaluation of Tissue Regeneration as Support in Translative Research
- Advances in Medical Device Materials. Part 2: Synthetic Collagen Fibers & Trimethylene Carbonate/Lactide/Glycolide Polymers
- Advances in Medical Device Materials. Part 1: Polycarbonate Resins
- The Basics of Bone Implantation, Part 3: Evaluation of a Bone Implantation Study
- UPLC/MS
- Don Palme at MD&M Minneapolis
- Moving From In Vitro to In Vivo: What Happens Next?
- The Basics of Bone Implantation, Part 2: Designing an Effective Bone Implantation Study
- The Basics of Bone Implantation, Part 1: Why Bone Implantation?
- New Developments in FDA Biocompatibility Requirements for Personal Lubricants
- New FDA Regulations on Laboratory-Developed Tests
- A Recent Human Anatomic Study Conducted with NAMSA
- Insights for Clinical Management
- NAMSA Receives AAALAC Accreditation for Preclinical Facility in Minnesota
- Introducing NAMSA Connect
- NAMSA’s Cell Culture Capabilities
Toxicology
- NAMSA Launches Online Biocompatibility Strategy Application to Streamline Development Efforts for Global Medical Device Manufacturers
- NAMSA Announces New Online Test Selection Tool to Support Global Medical Device Manufacturers
- Medical Device Development: Design Validation and Preclinical, Part 2
- Medical Device Development: Design Validation and Preclinical, Part 1
- Infographic: Common Mistakes in the Medical Device Development Continuum
- Evaluation of Tissue Regeneration as Support in Translative Research
- The Basics of Bone Implantation, Part 3: Evaluation of a Bone Implantation Study
- Don Palme at MD&M Minneapolis
- Moving From In Vitro to In Vivo: What Happens Next?
- The Basics of Bone Implantation, Part 2: Designing an Effective Bone Implantation Study
- The Basics of Bone Implantation, Part 1: Why Bone Implantation?
- New Developments in FDA Biocompatibility Requirements for Personal Lubricants
- Insights for Clinical Management
- Introducing NAMSA Connect
- NAMSA Speakers Around the Globe
- NAMSA's Anatomic Program
- Continuous Preclinical Monitoring in Medical Device Studies
- USP Class Testing
- Chinese Medical Device Market Continues to Grow
- The 2014 BPMDS Kicks Off In Germany
- NAMSA Adds BMP-2 Assay to a Comprehensive Breadth of Solutions for DBM Testing

Services
Resources
Login
- Subscriber Login
Company
International Sites
- United Kingdom
- France
- Germany
- Latin America
- China
- Japan

Copyright 2018 North American Science Associates Inc.

Site Map
Terms of Use
Privacy Statement
EU – U.S. and Swiss – U.S. Privacy Shield

Website Hosted and Maintained by MVP Marketing + Design

Type and Press “enter” to Search

NAMSA Network

Welcome to the NAMSA Network. Please log in here to update your profile, post comments on the blog; sign-up for events, webinars and classes; and receive email alerts to stay informed on the latest insights and updates.

If you are experiencing log in issues, please contact us at ldavidson@namsa.com or click here. We apologize for any inconvenience this may have caused.

Login

Username

Password

Remember Me

Need to register?

Lost your password?

NAMSA CONNECT

Click on the link below to access the NAMSA Connect client portal for sample submissions, testing reports, project tracking, and much more.

CONNECT

Reset Password

Username or E-mail: